The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD
/ analysis
B-Lymphocytes
/ pathology
Bone Marrow
/ pathology
Female
Flow Cytometry
Humans
Immunophenotyping
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Lymphoma, B-Cell
/ diagnosis
Lymphoma, Mantle-Cell
/ diagnosis
Male
Middle Aged
Prospective Studies
Receptor-Like Protein Tyrosine Phosphatases, Class 3
/ analysis
Young Adult
CD148
CD180
MYD88
flow cytometry
fluorescence in situ hybridization
mature B cell neoplasms
median fluorescence intensity
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
30
11
2020
received:
14
09
2020
accepted:
30
12
2020
pubmed:
18
1
2021
medline:
30
11
2021
entrez:
17
1
2021
Statut:
ppublish
Résumé
The categorization of mature B cell neoplasms (MBN) infiltrating blood and bone marrow are met with difficulties. The inclusion of CD148 and CD180 in the routine flow cytometry/FCM panels has been suggested to refine the diagnosis. We studied the discriminatory ability of CD148 and CD180 median fluorescence intensity(MFI), CD148/CD180 ratio and their expression relative to T cells (CD148 The flow cytometric (FCM) expression of CD148 and CD180 was studied prospectively in 102 patients (non-CLL; n = 72); diagnosed by a comprehensive panel of immunophenotypic and cytogenetic studies. The MFI and ratios were statistically compared across MBNs by Mann-Whitney U test. Cut-off values, sensitivity and specificity were calculated for significant parameters by receiver operator characteristic curve. CD180MFI > 4.35 showed 100% sensitivity and 90.9% specificity for a diagnosis of marginal zone lymphoma (MZL) while, CD148/180 > 5.15 was 100% specific and 81.8% sensitive for lymphoplasmacytic lymphoma. CD148 The current study shows an excellent utility of CD148MFI, CD180MFI, their ratio and relative expression levels in the subcategorization of immunophenotypically related MBNs.
Substances chimiques
Antigens, CD
0
CD180 protein, human
0
PTPRJ protein, human
EC 3.1.3.48
Receptor-Like Protein Tyrosine Phosphatases, Class 3
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123-1131Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
de la Fuente-García MA, Nicolás JM, Freed JH, et al. CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes. Blood. 1998;2800-2809.
Miguet L, Fornecker L, Wyrwas M, et al. Multicentric analyses of the CD148, CD180, and CD200 combination for the diagnosis of mature B-cell neoplasm using flow cytometry. Blood. 2015;126:2662.
Mayeur-Rousse C, Guy J, Miguet L, et al. GEIL (Groupe d'Etude Immunologique des Leucémies) CD180 expression in B-cell lymphomas: A multicenter GEIL study. Cytometry B Clin Cytom. 2016;90:462-466.
Sreedharanunni S, Sachdeva MU, Malhotra P, et al. Role of blood and bone marrow examination in the diagnosis of mature lymphoid neoplasms in patients presenting with isolated splenomegaly. Hematol. 2015;20:530-537.
Autschbach F, Palou E, Mechtersheimer G, et al. Expression of the membrane protein tyrosine phosphatase CD148 in human tissues. Tissue Antigens. 1999;54:485-498.
Miguet L, Lennon S, Baseggio L, et al. Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia. 2013;27:1748-1750.
Fan L, Miao Y, Wu YJ, et al. Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis. Leuk Lymphoma. 2015;56:3329-3335.
Miao Y, Wang R, Fan L, et al. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia. Int. J Clin Exp Pathol. 2015;8:7494-7498.
Mestrallet F, Sujobert P, Sarkozy C, et al. CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry B Clin Cytom. 2016;90:433-439.
Sorigue M, Junca J, Ferra C, et al. FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytometry B Clin Cytom. 2020;98(5):421-428. https://doi.org/10.1002/cyto.b.21890.
Autore F, Strati P, Laurenti L. Ferrajoli A Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018;103:931-938.
Rastogi P, Sreedharanunni S, Yanamandra U, Sachdeva MUS. Varma N Morphologic Confounders and CD19 Negativity in a Case of Hairy Cell Leukemia. Mediterr J Hematol Infect Dis. 2017;9:e2017033.
Gao J, Peterson L, Nelson B, Goolsby C. Chen YH Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009;132:699-706.
Virk H, Sreedharanunni S, Sachdeva MUS. Das A Mantle cell lymphoma with diminished expression of B-cell antigens: an unusual presentation. BMJ Case Rep. 2020;13:e235561.
Choi SM, Betz BL. Perry AM follicular lymphoma diagnostic caveats and updates. Arch Pathol Lab Med. 2018;142:1330-1340.
Morice WG, Chen D, Kurtin PJ, Hanson CA. McPhail ED Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinemia. Mod Pathol. 2009;22:807-816.
Raimbault A, Machherndl-Spandl S, Itzykson R, et al. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. Br J Haematol. 2019;184(4):625-633.
Porakishvili N, Kulikova N, Jewell AP, et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol. 2005;131:313-319.